Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(11):731-733; doi:10.1093/jnci/djj252
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Whitworth, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitworth, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Endostatin: Are We Waiting For Godot?

Ariel Whitworth

The first 150 words of the full text of this article appear below.

After trials of the angiogenesis inhibitor endostatin ended, Judah Folkman, M.D., of the Children's Hospital Boston and Harvard Medical School was dismayed.


Figure Removed (Available Only in the Full Text)
View larger version (101K):
[in this window]
[in a new window]
  		Judah Folkman

 
"There are four patients who have been on endostatin for 3.5 years or more with metastases of the liver. The tumors have stopped growing or arrested, mainly arrested. [The patients] love the drug. They don't lose their hair, they [maintain] normal weight, they're not nauseated, they go back to work, and they have strength."

But the clinical studies of endostatin stopped in February 2005, and supplies ran out a few months later. "After August 2, 2005, there was no more [endostatin] in the United States," said Folkman, whose laboratory discovered the molecule about a decade ago.

Endostatin is a protein produced by a fragment of the human gene collagen XVIII. Research by Folkman and others showed it could be a potent inhibitor of angiogenesis, a . . . [Full Text of this Article]

Clinical Trials

Defining the Mechanism

A Future in Endostar?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?